 We calculated convergent validity, defined as the correlation among drug rankings across frameworks.
1. Calculated mean scores for each drug.
2. Ranked mean scores of each of the 5 drugs within each framework from highest to lowest.
3. Compared rankings among the frameworks.
4. Kendall's W ranges from 0 (no agreement) to 1 (complete agreement). P values tested alternative hypothesis of complete agreement (W > 0) against null hypothesis.
5. Means were re-scaled to 0-100 for easy comparisons.
 We used inter-rater reliability as a measure of how stable frameworks' estimates of value are across users.
− Intraclass correlation coefficients (ICC) with 95% confidence intervals (CI) were chosen as the statistical measure.
− ICC was calculated separately for each framework.
− ICC calculations were done assuming the 8 reviewers represent a random sample from a larger population of reviewers.  Despite their common goals, it is unclear whether the frameworks actually provide valid and reliable measurements of value and how to assess such validity and reliability in practice.
A Novel Method for Evaluating Value Assessment Frameworks

METHODS
 Panelists were given a survey after completing the value assessments.
− Rated different frameworks − Provided comments regarding their experiences.
RESULTS
Presented at ISPOR EU, October 29-November 2, 2016, Vienna, Austria  This method is the first to allow quantitative analyses of value assessment frameworks' validity and reliability.
 When applied to 5 oncology drugs, this method successfully allowed us to draw conclusions about the convergent validity and inter-rater reliability of 4 value frameworks.
− Frameworks ranked similarly, indicating convergent validity.
− Overall, reliability was quite good.
− Reliability was better among oncologists and physicians for ASCO and ESMO, but not ICER.
− Individuals who want to conduct their own value assessments in oncology (rather than use a published value) should choose either ASCO or ESMO, because these two frameworks demonstrated high validity and reliability.
− Mean scores produced by a committee will be more reliable than those produced by an individual.
 Further exploration of differences among panelists will provide a better understanding of how to interpret value assessments produced by these frameworks in clinical practice.
 Although the approach can be used to determine the reproducibility of value assessments produced by these frameworks, reproducibility is only one component of an overall assessment of the frameworks' contribution to valuebased decision-making. Importantly, the method presented here fails to measure frameworks' construct validity -the extent to which they actually measure the latent variable, "value." The true test of this will be how they influence decisions made by clinicians and patients when used in clinical practice settings.
CONCLUSIONS
Panelists' Survey Results  ESMO instructions were the clearest.
 ASCO was rated most logically organized.
 No single frameworks emerged as:
− Easiest to use − Having highest global panelist rating (e.g., comfort with using framework to assess treatment for a loved one).
PhDs
Panelists
Reviewed published randomized controlled trial data for 5 drugs indicated for advanced lung cancer  Each assessment produced a single numeric or ordinal outcome (in aggregate the "panelist scores").
− Used along with NCCN's published assessments ("published scores") to evaluate convergent validity across 4 frameworks. − When re-scaled from 0 (worst) to 100 (best), score ranges varied among frameworks.
− ASCO and ESMO had wider ranges: 31 and 72 points, respectively.
− ICER and NCCN had much narrower ranges: 14 and 19 points, respectively.
• ASCO: 16-47
• ESMO: 25-97
• ICER: 80-94 
